Workflow
ATISER
icon
Search documents
上美股份:2025年报点评业绩高增,迈入多品牌多品类时代-20260327
Investment Rating - The report assigns a rating of "Accumulate" for the company [5]. Core Insights - The company is expected to achieve revenue and net profit growth of 35% and 44% year-on-year in 2025, respectively, with accelerated growth in the second half of the year [1]. - The brands Han Shu and Yi Ye are projected to have revenue growth of 32% and 134% year-on-year, respectively, indicating a strong outlook for the company's multi-category and multi-brand expansion [1]. - The report highlights the significant recovery of the Han Shu brand, with sales on Douyin increasing by 37% year-on-year, and the introduction of new mid-to-high-end brands is expected to enhance the product matrix [9]. Financial Summary - Total revenue is projected to reach 9,178 million RMB in 2025, reflecting a year-on-year increase of 35.1% [3]. - Gross profit is expected to be 7,015 million RMB in 2025, with a gross margin of 76.4%, up 1.2 percentage points year-on-year [9]. - The net profit attributable to the parent company is forecasted at 1,103 million RMB for 2025, representing a 41.1% increase year-on-year [3]. - The company anticipates a sales expense ratio of 58.4% and a management expense ratio of 3.5% for 2025, with a net profit margin of 12.6%, up 0.8 percentage points year-on-year [9]. Brand Performance - Revenue from the Han Shu brand is expected to reach 736 million RMB in 2025, growing by 32% year-on-year, while Yi Ye is projected to achieve 88 million RMB, with a remarkable growth of 134% [9]. - The report notes that the Yi Ye brand's top product, Anxin Cream, has seen a sales increase of 96% year-on-year, maintaining its position as the category leader [9]. - The company is expanding its brand matrix with the introduction of new products, including a mid-to-high-end anti-hair loss hair care brand and a skincare brand developed in collaboration with Shanghai Ninth People's Hospital [9].
上美股份(02145):2025年报点评:业绩高增,迈入多品牌多品类时代
Investment Rating - The report assigns a rating of "Accumulate" for the company [5]. Core Insights - The company is expected to achieve revenue and net profit growth of 35% and 44% year-on-year in 2025, respectively, with accelerated growth in the second half of the year [1]. - The brands Han Shu and Yi Ye are projected to have revenue growth of 32% and 134% year-on-year, respectively, indicating a strong multi-category and multi-brand expansion strategy [1]. - The report highlights the company's robust performance in the second half of 2025, with revenue, net profit, and attributable net profit expected to reach 5.07 billion, 598 million, and 579 million RMB, respectively, reflecting year-on-year growth of 54%, 53%, and 52% [9]. Financial Summary - The total revenue for 2024 is projected at 6,793 million RMB, increasing to 9,178 million RMB in 2025, representing a growth rate of 35.1% [3]. - Gross profit is expected to rise from 5,109 million RMB in 2024 to 7,015 million RMB in 2025, with a gross margin of 76.4%, an increase of 1.2 percentage points year-on-year [9]. - The attributable net profit is forecasted to grow from 781 million RMB in 2024 to 1,103 million RMB in 2025, reflecting a year-on-year increase of 41.1% [3]. - The report anticipates a PE ratio of 15.63 for 2024, increasing to 23.13 in 2025, before declining to 10.93 by 2028 [3]. Brand Performance - The Han Shu brand is expected to achieve a revenue of 736 million RMB in 2025, with a year-on-year growth of 32%, while Yi Ye is projected to reach 88 million RMB, with a remarkable growth of 134% [9]. - The report notes that Han Shu's sales on Douyin are expected to grow by 37% year-on-year, with significant growth also seen on platforms like Kuaishou and Pinduoduo [9]. - Yi Ye's flagship product, Anxin Cream, is projected to maintain its position as the top seller with a year-on-year sales increase of 96% [9].
化妆品医美行业周报:7月线上国货表现分化,业绩预告彰显强阿尔法-20250810
Investment Rating - The report maintains a "Buy" rating for the cosmetics and medical beauty sector, particularly highlighting companies like Shiseido and Up Beauty for their strong performance and growth potential [12][14]. Core Insights - The cosmetics and medical beauty sector underperformed the market during the week of August 1 to August 8, 2025, with the Shenwan Beauty Care Index growing by 1.7%, which is lower than the overall market performance [5][6]. - There is a notable divergence in the performance of domestic beauty brands in July, with strong growth observed in skincare brands like Han Shu and Marubi, while color cosmetics lagged due to weather and promotional timing [11][12]. - Up Beauty's H1 2025 performance exceeded expectations, with revenue projected between 4.09 to 4.11 billion yuan, reflecting a year-on-year growth of 16.8% to 17.3% [12][13]. Summary by Sections Industry Performance - The Shenwan Cosmetics Index increased by 1.3%, underperforming the Shenwan A Index by 0.6 percentage points, while the Shenwan Personal Care Index rose by 4.2%, outperforming the Shenwan A Index by 2.3 percentage points [5][6]. - The top-performing stocks in the sector included Up Beauty (+18.4%), Reliable Shares (+13.7%), and Lafang Home (+11.3%) [7]. Key Company Updates - Up Beauty's H1 2025 earnings report indicated a significant profit increase, with net profit margins improving due to optimized channel structures and a higher proportion of high-margin brands [12][13]. - Shiseido reported a 7.6% decline in sales for H1 2025, marking the largest drop in five years, with a notable decrease in the Chinese market [24]. E-commerce Insights - In July 2025, domestic beauty brands showed varied performance on major e-commerce platforms, with Han Shu achieving a 58% increase in GMV on Douyin, while color cosmetics faced challenges [20][21]. - The overall retail sales of cosmetics in June 2025 saw a decline of 2.3%, attributed to the pre-promotion of the 618 shopping festival [21][24]. Market Trends - The report highlights a shift in market dynamics, with domestic brands gaining market share against international competitors, particularly in the skincare segment [34][35]. - The Chinese skincare market is projected to reach 271.2 billion yuan in 2024, despite a 3.7% decline in growth [34][35].
上美股份(02145):上半年业绩增长靓丽,坚定看好公司多品牌发展战略
Orient Securities· 2025-08-07 06:11
Investment Rating - The report maintains a "Buy" rating for the company [2][5][10] Core Views - The company is expected to achieve significant revenue growth, with projected earnings per share (EPS) for 2025-2027 at 2.71, 3.42, and 4.19 RMB respectively, reflecting an upward adjustment from previous estimates [2][10] - The target price is set at 97.72 HKD, based on a 33x price-to-earnings (PE) ratio for 2025 [2][10] - The company has demonstrated strong performance in the first half of the year, with revenue growth driven by its main brand, Han Shu, and the rapid expansion of its infant brand, Yi Ye [9][10] Financial Information Summary - Revenue (in million RMB) is projected to grow from 4,191 in 2023 to 12,350 in 2027, with year-on-year growth rates of 56.6%, 62.1%, 24.7%, 22.3%, and 19.2% respectively [4][12] - Operating profit is expected to increase from 414 million RMB in 2023 to 1,739 million RMB in 2027, with significant growth rates of 308.5% in 2023 and 67.8% in 2024 [4][12] - Net profit attributable to the parent company is forecasted to rise from 461 million RMB in 2023 to 1,669 million RMB in 2027, with growth rates of 213.5% in 2023 and 69.4% in 2024 [4][12] - The gross margin is projected to improve from 72.1% in 2023 to 76.7% in 2027, while the net margin is expected to increase from 11.0% to 13.5% over the same period [4][12] Market Performance - The company's stock has shown strong absolute performance, with a 165.8% increase over the past 12 months [6] - The stock price as of August 6, 2025, was 87.75 HKD, with a 52-week high of 90.9 HKD and a low of 28.84 HKD [5]
上美股份(02145):业绩超预期,新品蓄势待发
Investment Rating - The report maintains a "Buy" rating for the company [3][8]. Core Insights - The company's performance exceeded expectations, with revenue and net profit both increasing. The estimated revenue for H1 2025 is approximately 4.09 to 4.11 billion RMB, representing a year-on-year growth of 16.8% to 17.3%, while net profit is expected to be between 540 to 560 million RMB, showing a year-on-year increase of 30.9% to 35.8% [8]. - The main brand, Han Shu, solidified its foundation with significant growth driven by category and channel adjustments. In July, Han Shu's GMV on Douyin increased by 58%, benefiting from a shift towards self-operated sales channels [8]. - New product launches and high-end breakthroughs are opening new growth avenues. The New Page brand in the maternal and infant sector saw a GMV increase of 187% from January to July, while the hair care segment is also gaining traction [8]. - The company's strategy of multi-brand collaboration and channel optimization is yielding long-term advantages, focusing on core sectors and expanding product categories [8]. Financial Data and Profit Forecast - Revenue projections for the company are as follows: - 2023: 4,191 million RMB - 2024: 6,793 million RMB - 2025E: 8,513 million RMB - 2026E: 10,466 million RMB - 2027E: 12,664 million RMB - The corresponding net profit forecasts are: - 2023: 461 million RMB - 2024: 781 million RMB - 2025E: 1,061 million RMB - 2026E: 1,364 million RMB - 2027E: 1,654 million RMB - The expected growth rates for net profit are 36% for 2025, 29% for 2026, and 21% for 2027 [7][9].